Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 360

1.

Intermittent blockade of OGFr and treatment of autoimmune disorders.

Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2018 Dec 12:1535370218817746. doi: 10.1177/1535370218817746. [Epub ahead of print]

PMID:
30541348
2.

Probing binding specificity of the sucrose transporter AtSUC2 with fluorescent coumarin glucosides.

De Moliner F, Knox K, Reinders A, Ward JM, McLaughlin PJ, Oparka K, Vendrell M.

J Exp Bot. 2018 Apr 27;69(10):2473-2482. doi: 10.1093/jxb/ery075.

3.

Can They Do That?: The Limits of Governmental Power over Medical Treatment.

McLaughlin PJ Jr.

J Leg Med. 2017 Jul-Dec;37(3-4):371-388. doi: 10.1080/01947648.2017.1385039. No abstract available.

PMID:
29473804
4.

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.

Ludwig MD, Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2018 Feb;243(4):361-369. doi: 10.1177/1535370217749830. Epub 2018 Jan 7.

PMID:
29307283
5.

Endogenous Opioids in the Etiology and Treatment of Multiple Sclerosis.

Zagon IS, McLaughlin PJ.

In: Zagon IS, McLaughlin PJ, editors. Multiple Sclerosis: Perspectives in Treatment and Pathogenesis [Internet]. Brisbane (AU): Codon Publications; 2017 Nov 27. Chapter 8.

6.

Topical Naltrexone Is a Safe and Effective Alternative to Standard Treatment of Diabetic Wounds.

McLaughlin PJ, Cain JD, Titunick MB, Sassani JW, Zagon IS.

Adv Wound Care (New Rochelle). 2017 Sep 1;6(9):279-288. doi: 10.1089/wound.2016.0725.

7.

Featured Article: Serum [Met5]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.

Ludwig MD, Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2017 Sep;242(15):1524-1533. doi: 10.1177/1535370217724791. Epub 2017 Aug 2.

8.

Idiosyncratic responses to climate-driven forest fragmentation and marine incursions in reed frogs from Central Africa and the Gulf of Guinea Islands.

Bell RC, Parra JL, Badjedjea G, Barej MF, Blackburn DC, Burger M, Channing A, Dehling JM, Greenbaum E, Gvoždík V, Kielgast J, Kusamba C, Lötters S, McLaughlin PJ, Nagy ZT, Rödel MO, Portik DM, Stuart BL, VanDerWal J, Zassi-Boulou AG, Zamudio KR.

Mol Ecol. 2017 Oct;26(19):5223-5244. doi: 10.1111/mec.14260. Epub 2017 Aug 24.

PMID:
28753250
9.

Selective opioid growth factor receptor antagonists based on a stilbene isostere.

Stockdale DP, Titunick MB, Biegler JM, Reed JL, Hartung AM, Wiemer DF, McLaughlin PJ, Neighbors JD.

Bioorg Med Chem. 2017 Aug 15;25(16):4464-4474. doi: 10.1016/j.bmc.2017.06.035. Epub 2017 Jun 27.

10.

Elevated serum [Met5]-enkephalin levels correlate with improved clinical and behavioral outcomes in experimental autoimmune encephalomyelitis.

Ludwig MD, Zagon IS, McLaughlin PJ.

Brain Res Bull. 2017 Sep;134:1-9. doi: 10.1016/j.brainresbull.2017.06.015. Epub 2017 Jun 21.

PMID:
28647454
11.

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.

Ludwig MD, Turel AP, Zagon IS, McLaughlin PJ.

Mult Scler J Exp Transl Clin. 2016 Sep 29;2:2055217316672242. doi: 10.1177/2055217316672242. eCollection 2016 Jan-Dec.

12.

A nonrandom subset of olfactory genes is associated with host preference in the fruit fly Drosophila orena.

Comeault AA, Serrato-Capuchina A, Turissini DA, McLaughlin PJ, David JR, Matute DR.

Evol Lett. 2017 May 9;1(2):73-85. doi: 10.1002/evl3.7. eCollection 2017 Jun.

13.

Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

McLaughlin PJ, Jagielo-Miller JE, Plyler ES, Schutte KK, Vemuri VK, Makriyannis A.

Psychopharmacology (Berl). 2017 Mar;234(6):1029-1043. doi: 10.1007/s00213-017-4548-2. Epub 2017 Feb 1.

PMID:
28144708
14.

CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in rats.

Thompson EE, Jagielo-Miller JE, Vemuri VK, Makriyannis A, McLaughlin PJ.

J Psychopharmacol. 2016 May;30(5):482-91. doi: 10.1177/0269881116639287. Epub 2016 Mar 22.

15.

Topical Application of Naltrexone to the Ocular Surface of Healthy Volunteers: A Tolerability Study.

Liang D, Sassani JW, McLaughlin PJ, Zagon IS.

J Ocul Pharmacol Ther. 2016 Mar;32(2):127-32. doi: 10.1089/jop.2015.0070. Epub 2016 Jan 7.

PMID:
26741052
16.

Genetics, Morphology, Advertisement Calls, and Historical Records Distinguish Six New Polyploid Species of African Clawed Frog (Xenopus, Pipidae) from West and Central Africa.

Evans BJ, Carter TF, Greenbaum E, Gvoždík V, Kelley DB, McLaughlin PJ, Pauwels OS, Portik DM, Stanley EL, Tinsley RC, Tobias ML, Blackburn DC.

PLoS One. 2015 Dec 16;10(12):e0142823. doi: 10.1371/journal.pone.0142823. eCollection 2015.

17.

Featured Article: Nuclear export of opioid growth factor receptor is CRM1 dependent.

Kren NP, Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2016 Feb;241(3):273-81. doi: 10.1177/1535370215605585. Epub 2015 Sep 30.

18.

MYC Analysis by Fluorescent In Situ Hybridization and Immunohistochemistry in Primary Adrenal Angiosarcoma (PAA): a Series of Four Cases.

Cornejo KM, Hutchinson L, Cyr MS, Nose V, McLaughlin PJ, Iafrate AJ, Sadow PM.

Endocr Pathol. 2015 Dec;26(4):334-41. doi: 10.1007/s12022-015-9385-4.

PMID:
26223194
19.

Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability.

Turel AP, Oh KH, Zagon IS, McLaughlin PJ.

J Clin Psychopharmacol. 2015 Oct;35(5):609-11. doi: 10.1097/JCP.0000000000000373. No abstract available.

PMID:
26203498
20.

Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.

Hammer LA, Waldner H, Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2016 Jan;241(1):71-8. doi: 10.1177/1535370215596384. Epub 2015 Jul 22.

Supplemental Content

Loading ...
Support Center